TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

This study is currently recruiting participants.

Verified May 2012 by Centers for Disease Control and Prevention

Sponsor:

Collaborator:

Sanofi

Information provided by (Responsible Party):

Centers for Disease Control and Prevention

ClinicalTrials.gov Identifier:

NCT00694629

First received: June 6, 2008

Last updated: May 7, 2012

Last verified: May 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	December 2012 (Final data collection date for primary outcome measure)

No publications provided by Centers for Disease Control and Prevention

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

To Top